Cell cycle regulation distinguishes lymphocytes from sporadic and familial Alzheimer's disease patients

Neurobiology of Aging

Volumn 32, Issue 12, 2011, Pages 2319.e13-2319.e26

  Bialopiotrowicz, Emilia ^a   Kuzniewska, Bozena ^a   Kachamakova Trojanowska, Neli ^a   Barcikowska, Maria ^b   Kuznicki, Jacek ^a,c   Wojda, Urszula ^a  

^a INTERNATIONAL INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Poland)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^c NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

Author keywords

Cell cycle; Familial Alzheimer's disease; Human immortalized B lymphocytes; PCR arrays; Presenilin 1 mutations; Sporadic Alzheimer's disease

Indexed keywords

CYCLIN A2; CYCLIN D1; CYCLIN E; CYCLIN E2; GAMMA SECRETASE; PROTEIN P21; UNCLASSIFIED DRUG;

ADULT; ALZHEIMER DISEASE; ARTICLE; CCNA2 GENE; CCND1 GENE; CCNE2 GENE; CDC25C GENE; CDKN1A GENE; CDKN2A GENE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL IMMORTALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; E2F2 GENE; ENZYME INHIBITION; FAMILIAL DISEASE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HDAC4 GENE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LYMPHOCYTE; MALE; MARKER GENE; ONCOGENE MYC; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SPORADIC ALZHEIMER DISEASE; TGFB1 GENE; YWHAH GENE;

EID: 80053641127     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2010.04.017     Document Type: Article

References (43)

1. Arendt T., Rodel L., Gartner U., Holzer M. Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimer's disease. Neuroreport 1996, 7:3047-3049.
2. Arendt T. Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the "Dr. Jekyll and Mr. Hyde concept" of Alzheimer's disease or the yin and yang of neuroplasticity. Prog. Neurobiol 2003, 71:83-248.
3. Beatty P.R., Krams S.M., Martinez O.M. Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines. J. Immunol 1997, 158:4045-4051.
4. Begg A.C., McNally N.J., Shrieve D.C., Karcher H. A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry 1985, 6:620-626.
5. Bhaskar K., Miller M., Chludzinski A., Herrup K., Zagorski M., Lamb B.T. The PI3K-Akt-mTOR pathway regulates Abeta oligomer induced neuronal cell cycle events. Mol. Neurodegener 2009, 16:4-14.
6. Boeras D.I., Granic A., Padmanabhan J., Crespo N.C., Rojiani A.M., Potter H. Alzheimer's presenilin 1 causes chromosome missegregation and aneuploidy. Neurobiol. Aging 2008, 29:319-328.
7. Bojarski L., Lewandowicz A., Blazejczyk M., Sobczak A., Kuznicki J., Wojda U. Biochemical properties of endogenous presenilin one and presenilin 2 in cultured human B-lymphocytes. Clin. Chem. Lab. Med 2007, 45:1273-1276.
8. Casoli T., Di Stefano G., Giorgetti B., Balietti M., Recchioni R., Moroni F., Marcheselli F., Bernardini G., Fattoretti P., Bertoni-Freddari C. Platelet as a physiological model to investigate apoptotic mechanisms in Alzheimer β-amyloid peptide production. Mech. Ageing Dev 2008, 129:154-162.
9. Coppedè F., Migliore L. DNA damage and repair in Alzheimer's disease. Curr. Alzheimer Res. 2009, 6:36-47.
10. Deters N., Ittner L.M., Gotz J. Substrate-specific reduction of PP2A activity exaggerates tau pathology. Biochem. Biophys. Res. Commun 2009, 379:400-405.
11. de las Cuevas N., Munoz U., Hermida O.G., Martin-Requero A. Altered transcriptional regulators in response to serum in immortalized lymphocytes from Alzheimer's disease patients. Neurobiol. Aging 2005, 26:615-624.
12. Dolbeare F.A., Gratzner H.G., Pallavicini M.G., Gray J.W. Flow cytometry measurement of total DNA content and incorporated bromodeoxyuridine. Proc. Natl. Acad. Sci. U. S. A. 1983, 80:5573-5577.
13. Dolcetti R., Masucci M.G. Epstein-Barr Virus: Induction and Control of Cell Transformation. J. Cell. Physiol 2003, 196:207-218.
14. Engidawork E., Gulesserian T., Seidl R., Cairns N., Lubec G. Expression of apoptosis related proteins in brains of patients with Alzheimer's disease. Neurosci. Lett 2001, 303:79-82.
15. Florean C., Zampese E., Zanese M., Brunello L., Ichas F., De Giorgi F., Pizzo P. High content analysis of gamma-secretase activity reveals variable dominance of presenilin mutations linked to familial Alzheimer's disease. Biochim. Biophys. Acta 2008, 1783:1551-1560.
16. Garner E., Raj K. Protective mechanisms of p53-p21-pRb proteins against DNA damage-induced cell death. Cell Cycle 2008, 7:277-282.
17. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
18. Heintz N. Cell death and the cell cycle: a relationship between transformation and neurodegeneration?. Trends Biochem. Sci 1993, 18:157-159.
19. Herrup K., Yang Y. Cell cycle regulation in the postmitotic neuron: oxymoron or new biology?. Nat. Rev. Neurosci 2007, 8:368-378.
20. Hoozemans J.J., Bruckner M.K., Rozemuller A.J., Veerhuis R., Eikelenboom P., Arendt T. Cyclin D1 and cyclin E are co-localized with cyclo-oxygenase 2 (COX-2) in pyramidal neurons in Alzheimer disease temporal cortex. J. Neuropathol. Exp. Neurol 2002, 61:678-688.
21. Hoozemans J.J., Stieler J., van Haastert E.S., Veerhuis R., Rozemuller A.J., Baas F., Eikelenboom P., Arendt T., Scheper W. The unfolded protein response affects neuronal cell cycle protein expression: implications for Alzheimer's disease pathogenesis. Exp. Gerontol 2006, 41:380-386.
22. Janicki S.M., Stabler S.M., Monteiro M.J. Familial Alzheimer's disease presenilin-one mutants potentiate cell cycle arrest. Neurobiol. Aging 2000, 21:829-836.
23. Kassner S.S., Bonaterra G.A., Kaiser E., Hildebrandt W., Metz J., Schroder J., Kinscherf R. Novel systemic markers for patients with Alzheimer disease?. - a pilot study. Curr. Alzheimer Res 2008, 5:358-366.
24. Lopes J.P., Blurton-Jones M., Yamasaki T.R., Agostinho P., laFerla F.M. Activation of cell cycle proteins in transgenic mice in response to neuronal loss but not amyloid-beta and tau pathology. J. Alzheimers Dis 2009, 16:541-549.
25. Maes O.C., Xu S., Yu B., Chertkow H.M., Wang E., Schipper H.M. Transcriptional profiling of Alzheimer blood mononuclear cells by microarray. Neurobiol. Aging 2007, 28:1795-1800.
26. Malik B., Currais A., Andres A., Towlson C., Pitsi D., Nunes A., Niblock M., Cooper J., Hortobagyi T., Soriano S. Loss of neuronal cell cycle control as a mechanism of neurodegeneration in the presenilin-one Alzheimer's disease brain. Cell Cycle 2008, 7:637-646.
27. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
28. McShea A., Lee H.G., Petersen R.B., Casadesus G., Vincent I., Linford N.J., Funk J.O., Shapiro R.A., Smith M.A. Neuronal cell cycle re-entry mediates Alzheimer disease-type changes. Biochim. Biophys. Acta 2007, 1772:467-472.
29. Migliore L., Fontana I., Trippi F., Colognato R., Coppedè F., Tognoni G., Nucciarone B., Siciliano G. Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients. Neurobiol. Aging 2005, 26:567-573.
30. Miller G., Lipman M. Comparison of the yield of infectious virus from clones of human and simian lymphoblastoid lines transformed by Epstein-Barr virus. J. Exp. Med 1973, 138:1398-1412.
31. Munoz U., Bartolome F., Esteras N., Bermejo-Pareja F., Martin-Requero A. Enhanced proteasone-dependent degradation of the CDK inhibitor p27 in immortalized lymphocytes from Alzheimer's dementia patients. Neurobiol. Aging 2008, 65:3507-3519.
32. Nagy Z., Combrinck M., Budge M., McShane R. Cell cycle kinesis in lymphocytes in the diagnosis of Alzheimer's disease. Neurosci. Lett 2002, 317:81-84.
33. Sie L., Loong S., Tan E.K. Utility of lymphoblastoid cell lines. J. Neurosci. Res 2009, 87:1953-1959.
34. Small S.A., Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 2008, 60:534-542.
35. Stieler J.T., Lederer C., Bruckner M.K., Wolf H., Holzer M., Gertz H.J., Arendt T. Impairment of mitogenic activation of peripheral blood lymphocytes in Alzheimer's disease. Neuroreport 2001, 12:3969-3972.
36. Tagami S., Okochi M., Fukumori A., Jiang J., Yanagida K., Nakayama T., Morihara T., Tanaka T., Kudo T., Takeda M. Processes of beta-amyloid and intracellular cytoplasmic domain generation by presenilin/gamma-secretase. Neurodegener. Dis 2008, 5:160-162.
37. Ungewitter E., Scrable H. Antagonistic pleiotropy and p53. Mech. Ageing Dev 2009, 130:10-17.
38. Wieder R. Selection of methods for measuring proliferation. Cell Growth, Differentiation and Senescence: A Practical Approach 1999, 1-32. Oxford University Press, New York. G.P. Studzinski (Ed.).
39. Woodhouse A., Shepherd C.E., Sokolova A., Carroll V.L., King A.E., Halliday G.M., Dickson T.C., Vickers J.C. Cytoskeletal alterations differentiate presenilin-one and sporadic Alzheimer's disease. Acta Neuropathol 2009, 117:19-29.
40. Yang Y., Herrup K. Cell division in the CNS: protective response or lethal event in post-mitotic neurons?. Biochim. Biophys. Acta 2007, 1772:457-466.
41. Yashin A.I., Ukraintseva S.V., Akushevich I.V., Arbeev K.G., Kulminski A., Akushevich L. Trade-off between cancer and aging: what role do other diseases play?. Evidence from experimental and human population studies. Mech. Ageing Dev 2009, 130:98-104.
42. Zekanowski C., Wojda U. Aneuploidy, chromosomal missegregation, and cell cycle reentry in Alzheimer's disease. Acta Neurobiol. Exp 2009, 69:232-253.
43. Zhang J., Kong Q., Zhang Z., Ge P., Ba D., He W. Telomere dysfunction of lymphocytes in patients with Alzheimer disease. Cogn. Behav. Neurol 2003, 16:170-176.